Literature DB >> 9233605

High affinity rheumatoid factor transgenic B cells are eliminated in normal mice.

H Wang1, M J Shlomchik.   

Abstract

Although systemic autoimmune diseases can be accompanied by multiple autoantibodies, certain specificities are dominant. Presumably, these specificities and their cognate Ags have properties that make them particularly amenable to autoimmune induction. Rheumatoid factors (RFs) are a dominant class of autoantibodies in rheumatoid arthritis and certain other autoimmune syndromes. To study the regulation of RFs in normal and autoimmune animals, we previously created a RF Ig transgenic model based on an RF isolated from an autoimmune MRL/lpr mouse. Using this model, called AM14, we were surprised to find that normal mice do not regulate disease-related RF B cells. This raised the question of whether RFs in general are not susceptible to tolerance induction, perhaps due to the unique properties of serum IgG and its FcRs. Alternatively, RFs can be tolerized, and the disease-related RFs are below the affinity threshold for such tolerance. To distinguish these possibilities, we generated a second RF transgenic model with the same specificity but much higher affinity than AM14. We found that, in contrast to AM14, high affinity RF B cells are subject to central tolerance, showing that there is not an absolute defect in RF B cell tolerance, but, rather, that RF B cell tolerance is affinity dependent even in normal animals. This is also the first model in which a disease-related specificity has been shown clearly to delete in a system in which Ag-positive and negative mice can be produced and compared.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9233605

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Antigen-specific responses in autoimmunity and tolerance.

Authors:  J W Thomas
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Understanding B-cell tolerance through the use of immunoglobulin transgenic models.

Authors:  Kirthi Raman Kumar; Chandra Mohan
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Reversing Tolerance in Isotype Switch-Competent Anti-Insulin B Lymphocytes.

Authors:  Jonathan M Williams; Rachel H Bonami; Chrys Hulbert; James W Thomas
Journal:  J Immunol       Date:  2015-06-24       Impact factor: 5.422

Review 4.  Regulation of autoreactive anti-IgG (rheumatoid factor) B cells in normal and autoimmune mice.

Authors:  H Wang; M J Schlomchik
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

5.  Requirement for Transcription Factor Ets1 in B Cell Tolerance to Self-Antigens.

Authors:  Lisa Russell; Shinu John; Jaime Cullen; Wei Luo; Mark J Shlomchik; Lee Ann Garrett-Sinha
Journal:  J Immunol       Date:  2015-09-09       Impact factor: 5.422

6.  FcγRIIB regulation of BCR/TLR-dependent autoreactive B-cell responses.

Authors:  Ana M Avalos; Melissa B Uccellini; Petar Lenert; Gregory A Viglianti; Ann Marshak-Rothstein
Journal:  Eur J Immunol       Date:  2010-10       Impact factor: 5.532

Review 7.  Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.

Authors:  Laurent Verkoczy
Journal:  Adv Immunol       Date:  2017       Impact factor: 3.543

8.  Autoantigen-specific B cell activation in Fas-deficient rheumatoid factor immunoglobulin transgenic mice.

Authors:  H Wang; M J Shlomchik
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

9.  Deletion and anergy of polyclonal B cells specific for ubiquitous membrane-bound self-antigen.

Authors:  Justin J Taylor; Ryan J Martinez; Philip J Titcombe; Laura O Barsness; Stephanie R Thomas; Na Zhang; Shoshana D Katzman; Marc K Jenkins; Daniel L Mueller
Journal:  J Exp Med       Date:  2012-10-15       Impact factor: 14.307

10.  Positive selection of anti-thy-1 autoreactive B-1 cells and natural serum autoantibody production independent from bone marrow B cell development.

Authors:  Kyoko Hayakawa; Masanao Asano; Susan A Shinton; Ming Gui; Li-Jun Wen; Joni Dashoff; Richard R Hardy
Journal:  J Exp Med       Date:  2003-01-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.